Subscribe
shutterstock_399778786_paul_brady_photography
Paul Brady Photography / Shutterstock.com
18 March 2021AmericasAlex Baldwin

FTC launches pharma merger analysis group

The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
24 January 2023   Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Big Pharma
US Judiciary Committee advances four bills to curb antitrust pharma practices
3 August 2021   The US Senate Judiciary Committee has unanimously voted to pass four bills that aim to crack down on anti-competitive practices in the pharmaceutical industry.
Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Generics
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
24 January 2023   Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Big Pharma
US Judiciary Committee advances four bills to curb antitrust pharma practices
3 August 2021   The US Senate Judiciary Committee has unanimously voted to pass four bills that aim to crack down on anti-competitive practices in the pharmaceutical industry.
Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

More on this story

Generics
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
24 January 2023   Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Big Pharma
US Judiciary Committee advances four bills to curb antitrust pharma practices
3 August 2021   The US Senate Judiciary Committee has unanimously voted to pass four bills that aim to crack down on anti-competitive practices in the pharmaceutical industry.
Big Pharma
FTC agrees to re-open Actavis and Watson merger decision
19 December 2018   The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims